1 Title Page:

2 Insulin-like growth factor 2 hypermethylation in peripheral blood leukocytes and colorectal

3 cancer risk and prognosis: a propensity score analysis of multiple-centre populations

- 4 Short Title: IGF2 and CRC risk and prognosis
- 5 HongRu Sun^{1#}, YanLong Liu^{2#}, YuXue Zhang³, Yibaina Wang¹, BinBin Cui², YaShuang Zhao^{1*}, YuPeng Liu^{1*}

6 Author affiliations:

- 7 HongRu Sun (<u>sunhongru_1024@126.com</u>), Yibaina Wang (<u>zhulin_vip@yeah.net</u>), YaShuang Zhao
- 8 (<u>zhao_yashuang@263.net</u>), and **YuPeng Liu** (<u>liuyupeng@wmu.edu.cn</u>), ¹Department of Epidemiology, Public Health
- 9 College, Harbin Medical University, 157 Baojian Street, Harbin 150081, Heilongjiang Province, China;
- 10 YanLong Liu (<u>liuyanlong1979@163.com</u>) and BinBin Cui (<u>cuibinbin222@hotmail.com</u>), ²Department of Colorectal
- 11 Surgery, The Third Affiliated Cancer Hospital of Harbin Medical University, 150 Haping Street, Harbin 150081,
- 12 Heilongjiang Province, China;
- 13 YuXue Zhang (<u>zhang yuxue@126.com</u>), ³Department of Hygiene Microbiology, Public Health College, Harbin Medical
- 14 University, 157 Baojian Street, Harbin 150081, Heilongjiang Province, China;
- [#]These authors have contributed equally to this work and share first authorship.
- 16 *These authors have contributed equally to this work and share last authorship.
- 17 *Corresponding Author: YuPeng Liu, Ph.D., Postal address: 157# Baojian Street, Nangang District, Harbin 150081,
- 18 Heilongjiang Province, China. Telephone: 86-(0)451-86611797, Fax: 86-(0)451-87502885, E-mail:
- 19 <u>liuyupeng@wmu.edu.cn;</u> ORCID: 0000-0002-8652-1987.
- 20 Author Contributors: HRS and YLL contributed equally to this work. YPL had full access to all of the data in the
- 21 initial study and take responsibility for the integrity of the data and the accuracy of the data analysis. YPL and YSZ
- 22 contributed to study conception and design. YPL, HRS, YBNW and YXZ contributed to DNA preparation and bisulfite
- 23 modification. YPL, HRS, YBNW, and YLL contributed to MS-HRM. YPL, HRS, YXZ, and YSZ contributed to
- 24 collection and assembly of data. YSZ, BBC, YPL, HRS, and YLL contributed to the analysis and interpretation of data.
- 25 YPL, YLL, BBC, YXZ and YSZ contributed to sample collection. YPL, HRS, YLL, YXZ and YSZ contributed to the
- 26 drafting of the initial versions of the manuscript. All authors contributed to the review and final approval of the
- 27 manuscript. YPL and YSZ were responsible for study supervision.
- 28 Conflict of Interests: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts

- 29 of Interest. The authors have declared that no conflict of interest exists. The funders had no role in the design of the study;
- 30 in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the
- 31 results.
- 32 Ethics approval: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by
- the Medical Ethics Committee of Harbin Medical University (1 Mar, 2014). All participants in the initial cohort provided
- 34 written informed consent. Informed consent was obtained from all subjects involved in the initial cohort. Written
- 35 informed consent has been obtained from the patients to publish this paper.
- 36 Grant support: This work was supported by the China Postdoctoral Science Foundation (grant number 2018M641875 to
- 37 YPL); the Natural Science Foundation of Heilongjiang Province (grant number YQ2019H021 to YPL); the National
- 38 Natural Science Foundation of China (grant number 81473055 to YSZ), and by grant from the SCORE Foundation
- 39 (Y-MX2016-045 to YLL).
- 40 Writing Assistance: The authors thank American Journal Experts for English language polishing of the manuscript.
- 41 Acknowledgments: The authors thank the participants and staff of both the initial study and the validation studies from
- 42 the GEO and TCGA for providing data and their valuable contributions. The authors thank the GEO and TCGA databases
- 43 for the access to the validation datasets. The authors thank Dr. Carlotta Sacerdote (Città della Salute e della Scienza
- 44 University) and Dr. Giovanni Fiorito (University of Sassari) for providing critical help in validation stage. The authors
- 45 thank Professor Wei Chen (Tulane University) for critically reading this manuscript.
- 46 Data Transparency Statement: Authors are willing to share any data that are used in this work. The data that support
- 47 the findings of the initial study are included in the manuscript and supporting file. The raw datasets used in the validation
- 48 stage are publicly available on GEO (http://www.ncbi.nlm.nih.gov/geo/) and TCGA (CORD and READ)
- 49 (https://cancergenome.nih.gov/).
- 50 Abbreviations: body mass index (BMI), carcinoembryonic antigen (CEA), confidence intervals (CIs), colorectal cancer
- 51 (CRC), CRC-specific survival (CSS), disease free survival (DFS), Gene Expression Omnibus (GEO), Harbin Medical
- 52 University (HMU), hazard ratios (HRs), insulin-like growth factor 2 (IGF2), loss of imprinting (LOI),
- 53 methylation-sensitive high-resolution melting (MS-HRM), odd ratios (ORs), overall survival (OS), peripheral blood
- 54 leukocytes (PBLs), propensity score (PS), The Cancer Genome Atlas (TCGA).
- 55 Word counts: Main Text 4918 words; Abstract 303 words; Figures 9; Tables 1; References 39; Supplementary Files 6
- 56 Keywords: IGF2 hypermethylation; colorectal neoplasms; risk; prognosis; propensity score analysis

57 ABSTRACT: (303 words)

Background: To comprehensively assess and validate the associations between insulin-like growth
factor 2 (*IGF2*) gene methylation in peripheral blood leukocytes (PBLs) and colorectal cancer (CRC)
risk and prognosis.

61 **Methods:** The association between *IGF2* methylation in PBLs and CRC risk was initially evaluated

62 in a case-control study and then validated in a nested case-control study and a twins' case-control

63 study, respectively. Meanwhile, an initial CRC patient cohort was used to assess the effect of *IGF2*

64 methylation on CRC prognosis and then the finding was validated in the EPIC-Italy CRC cohort and

65 TCGA datasets. A propensity score (PS) analysis was performed to control for confounders, and

66 extensive sensitivity analyses were performed to assess the robustness of our findings.

67 **Results:** PBL *IGF2* hypermethylation was associated with an increased risk of CRC in the initial

study (OR_{PS-adjusted}, 2.57, 95% CI: 1.65 to 4.03, P<0.0001), and this association was validated using

two independent external datasets ($OR_{PS-adjusted}$, 2.21, 95% CI: 1.28 to 3.81, P=0.0042 and

70 OR_{PS-adjusted}, 10.65, 95% CI: 1.26 to 89.71, *P*=0.0295, respectively). CRC patients with IGF2

71 hypermethylation in PBLs had significantly improved overall survival compared to those patients

with IGF2 hypomethylation (HR_{PS-adjusted}, 0.47, 95% CI: 0.29 to 0.76, P=0.0019). The prognostic

raising signature was also observed in the EPIC-Italy CRC cohort, although the HR did not reach statistical

ra significance (HR_{PS-adjusted}, 0.69, 95% CI: 0.37 to 1.27, *P*=0.2359).

75 **Conclusions:** IGF2 hypermethylation may serve as a potential blood-based predictive biomarker for

the identification of individuals at high risk of developing CRC and for CRC prognosis.

Funding: This work was supported by the China Postdoctoral Science Foundation (grant number

78 2018M641875 to YPL); the Natural Science Foundation of Heilongjiang Province (grant number

79 YQ2019H021 to YPL); the National Natural Science Foundation of China (grant number 81473055

to YSZ), and by grant from the SCORE Foundation (Y-MX2016-045 to YLL).

81 Clinical trial number: Not applicable.

82 MAIN TEXT (4918 words)

83 1. INTRODUCTION

84 Colorectal cancer (CRC) is the third-most common cancer in men and the second-most in women worldwide, with an estimated 1,931,590 newly diagnosed cases and 935,173 deaths in 2020, 85 accounting for approximately 1 in 10 cancer cases and deaths.^[12] In China, the number of CRC cases 86 has rapidly increased since the 1980s, with an estimated 555,477 newly diagnosed patients and 87 286,162 deaths in 2020, accounting for approximately 30% of all annually diagnosed CRC cases and 88 CRC-related deaths worldwide.^[2 3] The initiation and progression of CRC is multifactorial and 89 gradual with progressive accumulation of both genetic and epigenetic abnormalities, including 90 aberrant DNA methylation and loss of imprinting (LOI).^[4-6] The insulin-like growth factor 2 (*IGF2*) 91 gene is one of the first imprinted genes identified in humans. The IGF2 protein has a 92 tumour-promoting effect on existing colorectal neoplasia^[7-10] and that LOI of IGF2 in either tissue or 93 peripheral blood leukocyte (PBL) samples is associated with an increased risk of CRC.^[11 12] 94 Furthermore, a recent cohort study showed a significant association between *IGF2* hypomethylation 95 in paraffin-embedded tissues and poor CRC prognosis.^[13] However, no study has evaluated whether 96 97 PBL IGF2 methylation, which can be determined using non-invasive techniques, is associated with CRC risk or prognosis. 98

We therefore performed this study to comprehensively assess the association between PBL 99 100 IGF2 methylation status and CRC risk and prognosis. The propensity score (PS) method has been 101 increasingly used to reduce the likelihood of confounding bias in observational studies. It is a powerful statistical tool to control for confounding bias and is often more practical and statistically 102 103 more efficient than conventional strategies including covariate matching, stratified analysis, and multivariate statistical analysis.^[14 15] In this study, we used PS-based methods to assess the effect of 104 PBL IGF2 methylation on the risk of developing CRC, and then further validated our findings using 105 external datasets from EPIC-Italy CRC cohort and GEO.^[16-18] In addition, we used the same 106

- 107 PS-based methods to assess the association between IGF2 methylation and CRC prognosis using
- 108 CRC patient PBLs and tumour tissues, and then further validated our findings using external datasets
- 109 from EPIC-Italy CRC cohort and The Cancer Genome Atlas (TCGA).^[17 19]

110 **2. METHODS**

- 111 2.1. Study design and participants
- 112 **2.1.1. Initial study**
- 113 2.1.1.1. IGF2 methylation in PBLs and CRC risk

114 Descriptions of the study design and patient selection strategy have been published elsewhere.^[20 21]

Briefly, this hospital-based case-control study included 281 primary sporadic CRC patients

diagnosed (from June 2004 to May 2005 and May 2007 to January 2008) at the Cancer Hospital of

- 117 Harbin Medical University (HMU) and 147 CRC patients at the Second Affiliated Hospital of HMU
- (from October 2010 to December 2011) in Harbin, China (Figure 1). During the same time period,

119 428 cancer-free controls were selected from the Second Affiliated Hospital of HMU by individual

matching on gender and age (± 2 years). The basic characteristics of the CRC cases and controls are

shown in **Supplementary File 1A**. All participants provided written informed consent prior to

122 participation in the study. Blood samples were collected before surgery for the CRC patients and

before any therapy for the controls. This study was approved by the Ethics Committee of HMU.

All CRC patients had operable stage I-IV CRC, and their CRC diagnosis was histologically confirmed by a senior surgeon (YYL). Patients with adenomatous polyposis coli, who had a family history of CRC in first-degree relatives according to the Amsterdam criteria,^[22] or who received anti-cancer therapy before surgery were excluded.

128 2.1.1.2. IGF2 methylation in PBLs and CRC prognosis

129 The 281 CRC patients diagnosed at the Cancer Hospital of HMU were all included in the final CRC

130 cohort, while the 147 CRC patients from the Second Affiliated Hospital of HMU were excluded

131 because of the lack of follow-up information. For each patient, extensive demographic, clinicopathological and treatment information were extracted from the electronic medical record 132 system. All surgical operations were performed by the same surgical oncologists (BBC and YLL) 133 and all patients had negative surgical margins. The basic characteristics of the CRC patients included 134 in this cohort are shown in Supplementary File 1B. 135 136 The primary outcomes were overall survival (OS) from CRC diagnosis to death and disease 137 free survival (DFS) from CRC diagnosis to disease recurrence, metastasis, or death from CRC, 138 whichever came first. Another outcome was CRC-specific survival (CSS), which was defined as the time from disease diagnosis to CRC-specific death. Outcomes were observed during the follow-up 139

period through March 15, 2014 via an established protocol. Postoperative patients were followed up

141 at 3-6 months intervals for the first year and then annually. We used a telephone-delivery follow-up

142 questionnaire to collect information on the date and cause of death of the CRC patients. The recorded

date and cause of death of the CRC patients were validated using the medical certification of death

and the Harbin death registration system. Of the 281 eligible CRC patients included in this analysis,

- 145 127 died, 120 remained alive and 34 were lost to follow-up.
- 146 2.1.1.3. IGF2 methylation in tumour tissues and CRC prognosis

147 Fresh tumour tissues were collected during surgery from the CRC patients treated at the Cancer

Hospital of HMU, with written consent being obtained prior to surgery. Among the 298 eligible CRC

patients included in this analysis, 124 died, 141 remained alive and 32 were lost to follow-up. In all,

150 185 paired tumour tissue and PBL samples were obtained from the same patients.

151 2.1.1.4. Sample size

- 152 The sample size was estimated using PASS version 11.0.7 (NCSS LLC., USA). To assess whether
- aberrant methylation of insulin-like growth factor 2 (IGF2) in peripheral blood leukocytes (PBLs) is
- associated with the risk of developing colorectal cancer (CRC) in our present case-control study, we

estimated the sample size according to a logistic regression model. A sample size of 652 participants was needed to achieve 90% power (at the 5% level of statistical significance) in order to detect an odds ratio (OR) of 1.8 or more with a 20% prevalence in the control group. In addition, taking into consideration incomplete questionnaires and the failure rate for MS-HRM detection, we included approximately 20% more patients and finally targeted a total sample size of 800 participants (n = 400 for CRC patients and controls, respectively).

161 To assess whether aberrant IGF2 methylation in PBLs is associated with CRC patient 162 prognosis in our present cohort study, we estimated the sample size according to a Cox regression 163 model. A sample size of 184 CRC patients was needed to achieve 80% power (at the 5% level of

statistical significance) to detect a hazard ratio (HR) of 0.5 or 2.0 with an overall event rate of 50%
in this cohort. In addition, taking into consideration incomplete questionnaires and the failure rate for
MS-HRM detection, we included approximately 20% more patients and finally targeted a total

sample size of 221 CRC patients.

168 **2.1.2. Validation study**

A case-control study nested in the EPIC-Italy cohort (GSE51032) and a twins' case-control study (GSE89093) from the GEO were used to validate the association between PBL IGF2 methylation and CRC risk. We also used the EPIC-Italy CRC cohort and TCGA datasets (COAD and READ) to validate the relationship between IGF2 methylation in PBLs or tumour tissues and CRC prognosis, respectively. The basic characteristics of validation populations are shown in **Supplementary File 1**.

174 **2.2. Methylation analysis**

175 Sample processing, DNA extraction and bisulfite modification were performed as described

- 176 previously.^[20] Briefly, DNA was extracted from buffy coats and tumour tissues using a QIAamp
- 177 DNA Blood Mini Kit (Qiagen, Hilden, Germany, Cat#51106) and a DNeasy Blood & Tissue Kit
- 178 (Qiagen, Cat #69506), respectively. The DNA was then bisulfite-modified using an EpiTect Plus

179	DNA Bisulfite Kit (Qiagen, Cat#59826) according to the manufacturer's protocols. The
180	bisulfite-modified DNA sample was quantified using a NanoDrop 2000c bioanalyzer (Thermo-Fisher,
181	USA), diluted to a final concentration of 10 ng/ μ L and divided into aliquots for storage (-20 °C).
182	We designed a methylation-sensitive high-resolution melting (MS-HRM) assay for the IGF2
183	promotor region (101bp, GRCh38/hg38; chr11:2139870-2139971, including 11 CpG sites, Figure 2)
184	using Methprimer, ^[23] and IGF2 methylation status was tested with the researchers being blinded to
185	patient outcome. A set of methylation standards (100, 25, 10, 5, 2, 1, and 0% methylated DNA) were
186	prepared by mixing commercially available methylated and unmethylated DNA (Zymo Research,
187	Irvine, USA, Cat#D5014); these standards were used to semi-quantitatively measure the methylation
188	level of the IGF2 target region in the samples. The MS-HRM analysis was performed as previously
189	described. Briefly, each PCR mixture had a total volume of 10 μ L and contained 2× LightCycler 480
190	High Resolution Melting Master Mix (Roche Applied Science, Mannheim, Germany,
191	Cat#4909631001), 3 mmol/L MgCl2, 0.4 µmol/L of each primer (forward primer:
192	GGGATTTGGTTGAGGTTTTAAG; reverse primer: TACGACTAAAAAAACCCCCTAAACTC) and
193	1 μ L (approximately 10 ng) of bisulfite-modified template DNA. PCR conditions were as follows:
194	initial PCR activation (95 °C for 15 minutes); 55 3-step cycles (95 °C for 10 seconds, 56 °C for 30
195	seconds, and 72 °C for 20 seconds); and final extension (72 °C for 10 minutes). A blank control
196	(non-template control) sample was included in each batch, and all reactions were performed in
197	duplicate (as technical replicates). A third trial was conducted for the samples that presented
198	inconsistent results between the two trials. PCR amplification and MS-HRM analyses were
199	performed using the LightCycler 480 platform (Roche). After normalization of the melting curves
200	using the software module of Gene Scanning (Roche), two investigators (YP.L. and HR.S.), who
201	were blinded to the sample groups, independently assessed the MS-HRM data. Discrepancies were
202	resolved by discussion and consensus with another investigator (YBN.W.).

203 2.3. Covariates, Missing data analysis and imputation

204 All participants were interviewed face-to-face to complete a structured standard questionnaire, which was partially adopted from Shu et al.^[24] The questionnaire queried information on demographic 205 characteristics, lifestyle factors (including family history, smoking, alcohol consumption, 206 207 occupational physical activity), and diet. Dietary consumption over the past year was assessed using a validated food frequency questionnaire (FFQ).^[24] The FFQ included nine major food groups, which 208 represented most of the common foods in Northeast China. The food items included barbecued foods, 209 coarse grains, fish stewed with brown sauce, fresh fruits, fried foods, green vegetables, leftovers and 210 211 pork.

212 Questionnaire-derived covariates included: age ($< 60, \ge 60$), gender (male, female), BMI (< 24,

 \geq 24), family history of cancer other than CRC in first-degree relatives (no, yes), occupational

214 physical activity (blue-collar, white-collar), smoking status (no, yes), and consumption of barbecued

foods (< 1, \geq 1 times/week), coarse grains (< 50, \geq 50 g/week), fish stewed with brown sauce (< 1, \geq

1 times/week), fruits ($< 2, \ge 2$ times/week), fried foods ($< 1, \ge 1$ times/month), green vegetables (<

217 $100, \ge 100 \text{ g/day}$), leftovers (< 1, ≥ 1 times/week) and pork (< 250, $\ge 250 \text{ g/week}$). All

218 questionnaire-derived variables were analysed via missing value analysis and were imputed via

219 multiple imputations as described in our previous study.^[20]

220 2.4. Statistical analysis

221 Means and standard deviations were reported for continuous variables, while counts and frequencies 222 were reported for categorical variables. Covariate differences between groups were compared using 223 the standardised differences method with a significant imbalance level of standardised difference \geq 25%. In the CRC risk analysis, we first categorised individuals into two groups according to the 224 optimal cut-off point for the IGF2 methylation level ($\leq 1\%$ hypomethylation group; > 1%225 hypermethylation group), which was determined using the receiver operating characteristic (ROC) 226 227 curve and the Youden index method with case-control status as the dependent variable (0 for controls; 228 1 for cases). We then conducted univariate and multivariate logistic regression analyses and reported

229	odd ratios (ORs) and 95% confidence intervals (CIs) to assess the association between IGF2
230	methylation status and CRC risk. In the CRC prognosis analysis, the cut-off point for the IGF2
231	methylation level was also 1% using the same method with overall survival time as the dependent
232	variable (0 for less than median survival time; 1 for longer than or equal to median survival time).
233	According to this cut-off point, CRC patients were categorised into IGF2 hypomethylation and IGF2
234	hypermethylation groups (206 and 75 cases, respectively). Kaplan-Meier curves and log-rank tests
235	were used to compare OS, DFS or CSS between groups. The associations between IGF2 methylation
236	and OS, DFS or CSS were estimated using univariate and multivariate Cox regression models and
237	reported as hazard ratios (HRs) and 95% CIs. Two-sided statistical significance was defined as
238	P<0.05. ROC analyses were performed with MedCalc version 15.4 (Ostend, Belgium) and all other
239	statistical analyses were performed with SPSS Statistics version 23.0 (IBM, Inc., USA).
240	To minimise group differences on covariates, we performed a PS-based analysis. In the CRC
241	risk analysis, the PS was calculated with case-control status as the dependent variable using a
242	multivariate logistic regression model that included demographic and lifestyle factors
243	(Supplementary File 2A). In the survival analysis, the PS was calculated with IGF2 methylation as
244	the dependent variable using a multivariate logistic regression model that included demographic and
245	lifestyle factors and clinicpathological characteristics (Supplementary File 2B). To incorporate all
246	the patients in the analyses, we primarily employed the PS-adjustment method. ^[14] Additionally,
247	several PS-based methods, including stratification by quintile of PS, weighting with inverse
248	probability of treatment weights, and individual PS matching, were also performed as sensitivity
249	analyses.
250	For PS-stratification analyses, all patients were stratified by PS quintile. HRs for PS-stratified
251	analyses were obtained by pooling effect estimates from each PS quintile. For PS-weighted analyses,

each patient was weighted by the inverse probability of being in the higher versus lower IGF2

253 methylation groups; this method is known as weighting with inverse probability of treatment weights

(IPTW). The weight for each patient was calculated according to the method described by Robins
and Hernan:^[25] Pt/PS and (1-Pt)/(1-PS) for patients in the IGF2 hypermethylation and
hypomethylation groups, respectively; where Pt is the proportion of the patients with IGF2
hypermethylation in all participants. In addition to using PS as an adjustment or weighting factor in
the analysis model, PS was also used for individual matching. PS matching was performed using a
nearest-neighbour algorithm with a calliper of 0.2 (which means that the maximum allowable PS
difference between groups was no larger than 20% of the standard deviation of PS).

261 **2.5.** Sensitivity analysis

To assess the robustness of our results, we performed extensively predefined sensitivity analyses. 262 First, to evaluate the potential impact of the PS-adjusted confounders on our results in the initial 263 264 study, we performed confounding RR analysis, which was defined as the ratio of the PS-adjusted effect estimates and the unadjusted effect estimates.^[26] To investigate whether potential residual 265 confounders could impact the results, we calculated the E-value for PS-adjusted effect estimates and 266 the limit of the CI closest to the null.^[27] Finally, we performed subgroup analyses according to the 267 tumour location (colon or rectum), UICC stage, gender (female vs. male), age (≥ 60 vs. < 60 years), 268 and body mass index (BMI, >24 vs. <24). 269

270 Additionally, we performed several post hoc sensitivity analyses. To test whether tumour load 271 impacts IGF2 methylation level in PBLs, we assessed the associations between IGF2 methylation 272 and UICC stage and serum carcinoembryonic antigen (CEA) level. We also tested whether PBL 273 IGF2 methylation levels could have been impacted by leukocyte count and the percentage of certain subpopulations. In addition, to comprehensively determine the association between IGF2 274 275 methylation and CRC risk, we combined the results from the initial case-control and the validation studies using a meta-analysis method of random effect model. Finally, we explored whether PBL 276 277 IGF2 methylation levels differ between the CRC patients included in the survival analysis and those 278 excluded.

279 **3. RESULTS**

3.1. IGF2 methylation in PBLs and CRC risk

- As shown in Figure 3A, subjects with IGF2 hypermethylation (15.54%), compared to subjects with
- IGF2 hypomethylation (84.46%), had a significantly increased CRC risk (PS-adjusted OR, 2.57, 95%)
- 283 CI: 1.64-4.03; P<0.001). This association remained statistically significant even after subgroup
- analyses. Notably, stratified analyses showed a positive association only in UICC stage I-III but not
- in stage IV cancers.
- In the EPIC-Italy dataset, IGF2 hypermethylation was also significantly associated with an
- increased CRC risk (OR, 2.21, 95% CI: 1.28-3.81; P=0.004). Subgroup analyses showed the
- association was statistically significant in distal colon cancer, men, and older subjects (Figure 3A).
- Using the GSE89093 dataset, IGF2 hypermethylation was strongly associated with an increased risk
- 290 of CRC or colon cancer alone. After pooling the results from these three datasets, the observed
- association was still significant (**Figure 3B**).

292 **3.2. IGF2 methylation in PBLs and CRC prognosis**

293 The Kaplan-Meier survival curves for the PBL IGF2 hypermethylation and hypomethylation groups

- are shown in **Figure 4**. The median OS was 73 months (95% CI: 66-80 months) in the IGF2
- hypermethylation group versus 56 months (95% CI: 52-61 months) in the hypomethylation group.
- The OS rate was 75% (95% CI: 60-80%) in the IGF2 hypermethylation group versus 62% (95% CI:
- 297 50-57%) in the hypomethylation group (HR_{PS-adjusted}, 0.47, 95% CI: 0.29-0.76; *P*=0.002). The CSS
- ²⁹⁸ rate was 56% (95% CI: 45-68%) in the IGF2 hypermethylation group versus 38% (95% CI: 31-45%)
- in the hypomethylation group (HR_{PS-adjusted}, 0.49, 95% CI: 0.30-0.80; *P*=0.004). The median DFS was
- 300 66 months (95% CI: 57-74 months) in the IGF2 hypermethylation group versus 52 months (95% CI:
- 48-57 months) in the hypomethylation group (HR_{PS-adjusted}, 0.53, 95% CI: 0.32-0.85; P=0.009). Based
- 302 on subgroup analyses, we found that the statistically significant association persisted in rectal cancers,

303 UICC stage I-III cancers, males, older, or normal body weight patients. In contrast, the effect

- 304 estimates did not reach statistical significance in colon cancers, stage IV cancers, females, younger,
- and overweight or obese patients (Table 1).
- 306 Using the follow-up results of the 166 CRC patients from the EPIC-Italy cohort, we observed a
- clear trend for a longer OS related with IGF2 hypermethylation, although the association was not
- statistically significant. The univariate HR was 0.65 (95% CI: 0.35-1.19; P=0.164;), and after PS
- adjustment, the HR_{PS-adjusted} was 0.69 (95% CI: 0.37-1.27; *P*=0.236; K-M survival curves are shown
- 310 in **Figure 5**).

311 **3.3. IGF2 methylation in tissues and CRC prognosis**

In our initial study, the association between IGF2 methylation in tumour tissues and CRC patient

survival did not reach statistical significance (Figure 6A), and this result was confirmed by the

- TCGA dataset (Figure 6B). Using IGF2 mRNA expression data in tumour tissues, we found an
- obvious negative correlation with IGF2 methylation (r=-0.24, P<0.001; Figure 6C). So we further
- explored whether IGF2 mRNA expression levels impact the disease prognosis but found no
- 317 statistically significant association (**Figure 6D**).

318 **3.4.** Sensitivity analysis

319 We repeated analyses using other PS-based methods and the results were consistent with the

PS-adjustment results (Supplementary File 3). Based on the confounding RR analysis (Figure 7),

- 321 we did not find any substantial differences between the PS-adjusted effect estimates and the
- 322 corresponding unadjusted effect estimates. Furthermore, the E-value analysis showed that our
- findings in both the initial and validation studies appear to be very robust (Supplementary File 4).
- We found no evidence for an obvious impact of UICC stages on IGF2 methylation in PBLs. Of
- note, IGF2 hypermethylation was significantly more frequent in the CEA-low group than in the
- 326 CEA-high group (34.15% vs. 20.89%, P=0.013). We found no significant relationship between the

PBL IGF2 methylation levels and the leukocyte count or the percentages of certain leukocyte
subpopulations. Finally, we analysed samples from 147 additional CRC patients that were excluded
from the survival analysis and found no differences in their PBL IGF2 methylation levels compared
to those of the 281 CRC patients included in the survival analysis (Supplementary File 5).

331 4. DISCUSSION

In this study, we first assessed the impact of the PBL IGF2 methylation status on the risk and prognosis of CRC. We found that individuals with IGF2 hypermethylation in their PBLs were at significantly higher risk of developing CRC than those with IGF2 hypomethylation. However, our findings showed better survival rates in CRC patients with PBL IGF2 hypermethylation compared to those in CRC patients with IGF2 hypomethylation.

337 In our initial case-control study, it is not possible to determine the aetiologically relevant time window of IGF2 methylation relative to CRC development. Fortunately, the prospective nature of the 338 EPIC-Italy cohort is invaluable for confirming the temporal sequence of DNA methylation and CRC 339 onset and therefore helps to distinguish causal from consequential epigenetic changes.^[28 29]. In this 340 341 nested case-control study, blood samples from CRC patients were collected 0.02-14.40 years 342 (average 6.16 years) before diagnosis. Using this dataset, we found a positive but non-significant association between PBL IGF2 hypermethylation and an increased CRC risk. To account for reverse 343 causality, we repeated the analyses excluding subjects who developed CRC within two years after 344 their blood sampling and found that this positive association remained significant (PS-adjusted OR, 345 346 2.08, 95% CI: 1.18-3.69; P=0.012). Furthermore, our main finding was verified using the GSE89093 dataset. Finally, we pooled the results from these three datasets and found a 2.19-fold higher risk of 347 348 developing CRC in the IGF2 hypermethylation group compared to the hypomethylation group. 349 The exact mechanism that links alterations in the IGF2 methylation status in PBLs and the

350 susceptibility for CRC remains unclear. The PBL-derived DNA methylation profiles represent the

overall methylation status of an individual. Alterations in PBL-derived DNA may be constitutively 351 present before cancer occurs or represent an early response of the haematology system to the 352 presence of tumour cells after cancer develops. Imprinting of IGF2 is primarily maintained by DNA 353 methylation.^[30 31] It has been reported that imprinting and expression are controlled by CpG-rich 354 regions upstream of the IGF2 promotors. Normally, IGF2 is expressed from the paternal allele only, 355 while the maternal allele is methylated and imprinted. Several previous studies have reported that the 356 357 loss of imprinting (LOI) of IGF2 in peripheral blood (leukocytes or lymphocytes) may be a potential biomarker for the risk of developing CRC,^[12 32] and IGF2 methylation alterations were suggested as 358 a surrogate marker for LOI of IGF2.^[32 33] If IGF2 aberrant methylation is merely a surrogate marker 359 for LOI of IGF2, then IGF2 hypermethylation would be expected to be beneficial for maintaining the 360 imprinting status of IGF2 and thus should decrease the risk of developing CRC. On the contrary, our 361 362 results showed that IGF2 hypermethylation increases the risk of developing CRC, indicating that 363 IGF2 participates in CRC tumorigenesis through two different modes of epigenetic alteration, aberrant hypermethylation and LOI, which is supported by previous studies.^[34 35] Thus, our findings 364 365 demonstrate that aberrant IGF2 hypermethylation can be assayed with a blood-based test and that the PBL IGF2 methylation status is likely to be a valuable predictive biomarker for CRC risk, 366 independent of LOI of IGF2. 367

368 Further analysis of the GEO and TCGA datasets provided additional evidence supporting the 369 association between IGF2 hypermethylation and the risk of developing CRC. For example, using 370 these datasets we found significant associations between IGF2 hypermethylation in tissues and an increased risk of CRC or adenomas (Figures 8A-D). Interestingly, colorectal adenomas, a 371 372 precancerous condition, showed similar levels of IGF2 methylation compared to tumour tissues (Figure 8E). Most colorectal cancers initially develop as benign precursor lesions (adenomas) that 373 can take as long as 10 to 15 years to develop into carcinomas, which underpins early detection and 374 removal of adenomas as an important strategy for preventing CRC.^[6 36] The findings from the GEO 375

376	and TCGA datasets indicate that IGF2 methylation in tissues can discern colorectal adenomas or
377	CRCs from normal intestinal mucosa, which also suggests that IGF2 methylation may prove valuable
378	during CRC screening for early cancer detection. We were unable to evaluate the association
379	between IGF2 methylation in PBLs and the risk of developing adenomas. This issue should be
380	explored in future studies.
381	In 2008, Ito and colleagues used peripheral blood samples to assess six CpG sites located in
382	the IGF2 gene and reported that IGF2 methylation is not statistically associated with CRC risk. ^[34]
383	However, the region tested in Ito's study is different from the region examined in our study. As
384	shown in Figure 2, the differentially methylated region assessed in our study is located near the TSS.
385	To further validate our findings, we used the EPIC-Italy dataset to evaluate the methylation status of
386	a relatively large region of -1500 bp upstream to +1500 bp downstream from the TSS. This
387	sensitivity analysis again showed a statistically significant association between IGF2

388 hypermethylation and CRC risk (OR, 1.75, 95% CI: 1.15-2.66; *P*=0.009).

For the first time, we assessed the prognostic value of PBL IGF2 methylation status in CRC patients and found that patients with IGF2 hypermethylation in PBLs had significantly improved survival compared to patients with IGF2 hypomethylation. These findings were especially obvious for stage I-III CRC patients. However, this association did not reach statistical significance in the external EPIC-Italy CRC cohort. Given these inconsistent results, further cohorts with large sample size are needed to validate this novel finding.

For sensitivity analysis, we also evaluated the association between PBL IGF2 methylation and CRC prognosis during different follow-up periods. We observed a significantly strong association for 5-year relative survival, while the associations for both 1-year and 3-year relative survival were not statistically significant. Based on these results, it is hypothesised that the beneficial effects of IGF2 hypermethylation on CRC survival might begin the fifth year following CRC diagnosis and might persist for several years. In fact, the potentially beneficial effects may occur as early as the first year

after CRC diagnosis, even though this effect did not reach statistical significance. The limited sample
size of the cohort study may hinder the interpretation of these results; therefore, larger cohort studies
are required to further evaluate this issue.

We also evaluated the impact of IGF2 methylation in tumour tissues on CRC patient survival 404 405 and found no statistically significant association in both our initial cohort and the TCGA datasets. This is in consistent with a recent research.^[7] However, two previous studies from Japan have 406 assessed the IGF2 methylation status in tumour tissues of CRC patients and the results were 407 inconsistent.^[13 37] The region tested in those two studies is different from that examined in our study. 408 The lack of consistency between the results from the PBL samples and tumour tissues may reflect the 409 410 fact that IGF2 methylation is merely a predictive marker rather than a prognostic marker. In addition, 411 the detection of tissue-based markers depends on material from a biopsy or tumour tissue from resection. Because of intratumour heterogeneity, the detection of a biomarker from a single biopsy or 412 one section of a tumour tissue sample might not necessarily represent the IGF2 methylation status of 413 a given patient. Repeated biopsies and tests of multiple samples, however, are not feasible in routine 414 clinical practice. Fortunately, blood-derived biomarkers have the potential to overcome these 415 416 problems. In this respect, repeat blood sampling and detection of PBL IGF2 methylation is more acceptable and feasible than repeat biopsies in the clinic. Given that CRC has a wide range of 417 418 long-term outcomes, PBL IGF2 methylation, as a DNA-based non-invasive blood test, could prove 419 beneficial during follow-up and help identify patients at high risk of disease recurrence and 420 progression.

An important aspect and potential concern of using PBL DNA methylation as a biomarker is whether leukocyte subpopulations affect the methylation signature of an individual. To address this concern, we collected patient clinical records including leukocyte counts and included these data as covariates in the PS model. Theoretically, the PS adjustment would control for the potential impact of different leukocyte counts and different subpopulations on our results. We compared the results

before and after including the leukocyte count data in the PS model and found similar results
(Supplementary File 6), suggesting that the effect of leukocyte counts and subpopulations on our
results is negligible. Additional evidence supporting these findings can be found in several recently
published studies which also showed that differences in leukocyte subpopulations were unlikely to
interfere with the results of PBL-derived DNA methylation.^[38 39]

431 Interestingly, our data indicates that PBL IGF2 hypermethylation correlates with serum CEA 432 levels before surgery. Therefore, we further assessed whether the association between PBL IGF2 433 methylation and CRC prognosis is impacted by CEA levels. Using the additive model, we found a positive interaction between PBL IGF2 methylation and CEA on CRC prognosis (Figure 9). Given 434 the limited sample size of the subgroups, this aspect should be further validated in future studies. Of 435 436 note, after adjustment for CEA and the interaction between IGF2 methylation and CEA, the effect of IGF2 hypermethylation itself on CRC prognosis remained statistically significant (HR, 0.44, 95% CI: 437 0.24-0.79; P=0.006), suggesting a robust and independent role for PBL IGF2 hypermethylation in 438 predicting the prognosis of CRC. 439

This study has several strengths. The findings from our initial studies were validated with several external datasets. In our initial CRC patient cohort, the covariates were collected prospectively and were blinded to patient outcome. We used PS techniques to control for multiple potential confounding factors. Furthermore, we performed extensive sensitivity analyses to assess the robustness of our findings. The confounding RR and the E-value sensitivity analyses demonstrated that our results are unlikely to be substantially impacted by both the adjusted confounders included in the PS models or a potential residual confounder.

In our present cohort, adjuvant chemotherapy was not offered routinely to high risk individuals.
Thus, we did not analyse the clinical significance of IGF2 methylation as a predictive biomarker for
sensitivity to adjuvant chemotherapy. Further studies are needed to explore and clarify this issue.
Another potential limitation is the limited sample size used in the stratified analyses. Therefore, the

451 results from the stratified analyses should be interpreted with caution.

452 **5. CONCLUSIONS**

- 453 In summary, IGF2 methylation in PBLs is significantly associated with the risk and prognosis of
- 454 CRC, suggesting an important role for IGF2 methylation as a blood-based predictive biomarker to
- identify of individuals at high risk of developing CRC; meanwhile, PBL IGF2 methylation might
- also serve as a predictive biomarker for CRC prognosis.

457 **REFERENCES**

- Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and
 Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* 2021;71:209-49.
- Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2018). Global
 Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer.

462 https://gco.iarc.fr/today/home (Accessed November 7, 2021).

- 463 3. Cao W, Chen HD, Yu YW, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of
 464 the global cancer statistics 2020. *Chin Med J (Engl)* 2021;134:783-91.
- 465 4. Dekker E, Tanis PJ, Vleugels JLA, et al. Colorectal cancer. *Lancet* 2019;394:1467-80.
- 466 5. Jones PA, Baylin SB. The epigenomics of cancer. *Cell* 2007;128:683-92.
- 467 6. Kuipers EJ, Grady WM, Lieberman D, et al. Colorectal cancer. Nat Rev Dis Primers 2015;1:15065.
- 468 7. Hidaka H, Higashimoto K, Aoki S, et al. Comprehensive methylation analysis of imprinting-associated differentially
 469 methylated regions in colorectal cancer. *Clin Epigenetics* 2018;10:150.
- 470 8. Unger C, Kramer N, Unterleuthner D, et al. Stromal-derived IGF2 promotes colon cancer progression via paracrine
 471 and autocrine mechanisms. *Oncogene* 2017;36:5341-55.
- 472 9. Rogers MA, Kalter V, Strowitzki M, et al. IGF2 knockdown in two colorectal cancer cell lines decreases survival,
 473 adhesion and modulates survival-associated genes. *Tumour Biol* 2016;37:12485-95.
- Bergman D, Halje M, Nordin M, et al. Insulin-like growth factor 2 in development and disease: a mini-review.
 Gerontology 2013;59:240-9.
- the second sec
- 478 12. Cui H, Cruz-Correa M, Giardiello FM, et al. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk.
 479 *Science* 2003;299:1753-5.
- Baba Y, Nosho K, Shima K, et al. Hypomethylation of the IGF2 DMR in colorectal tumors, detected by bisulfite
 pyrosequencing, is associated with poor prognosis. *Gastroenterology* 2010;139:1855-64.
- 482 14. Elze MC, Gregson J, Baber U, et al. Comparison of Propensity Score Methods and Covariate Adjustment:
 483 Evaluation in 4 Cardiovascular Studies. *J Am Coll Cardiol* 2017;69:345-57.
- 484 15. Haukoos JS, Lewis RJ. The Propensity Score. JAMA 2015;314:1637-8.
- 485 16. Gene Expression Omnibus. Available at: https://www.ncbi.nlm.nih.gov/geo/. Accessed May 22, 2020.
- Cordero F, Ferrero G, Polidoro S, et al. Differentially methylated microRNAs in prediagnostic samples of subjects
 who developed breast cancer in the European Prospective Investigation into Nutrition and Cancer (EPIC-Italy)
 cohort. *Carcinogenesis* 2015;36:1144-53.

489	18.	Roos L, van Dongen J, Bell CG, et al. Integrative DNA methylome analysis of pan-cancer biomarkers in cancer
490		discordant monozygotic twin-pairs. Clin Epigenetics 2016;8:7.
491	19.	The Cancer Genome Atlas Program. Available at: https://cancergenome.nih.gov/. Accessed February 4, 2020.
492	20.	Liu Y, Wang Y, Hu F, et al. Multiple gene-specific DNA methylation in blood leukocytes and colorectal cancer risk:
493		a case-control study in China. Oncotarget 2017;8:61239-52.
494	21.	Sun H, Huang H, Li D, et al. PBX3 hypermethylation in peripheral blood leukocytes predicts better prognosis in
495		colorectal cancer: A propensity score analysis. Cancer Med 2019;8:4001-11.
496	22.	Vasen HF, Watson P, Mecklin JP, et al. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC,
497		Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology
498		1999;116:1453-6.
499	23.	Li LC, Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics 2002;18:1427-31.
500	24.	Shu XO, Yang G, Jin F, et al. Validity and reproducibility of the food frequency questionnaire used in the Shanghai
501		Women's Health Study. Eur J Clin Nutr 2004;58:17-23.
502	25.	Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology.
503		<i>Epidemiology</i> 2000;11:550-60.
504	26.	Greenland S, Pearce N. Statistical foundations for model-based adjustments. Annu Rev Public Health
505		2015;36:89-108.
506	27.	VanderWeele TJ, Ding P. Sensitivity Analysis in Observational Research: Introducing the E-Value. Ann Intern Med
507		2017;167:268-74.
508	28.	Langevin SM, Houseman EA, Accomando WP, et al. Leukocyte-adjusted epigenome-wide association studies of
509		blood from solid tumor patients. Epigenetics 2014;9:884-95.
510	29.	Rakyan VK, Down TA, Balding DJ, et al. Epigenome-wide association studies for common human diseases. Nat
511		Rev Genet 2011;12:529-41.
512	30.	Ransohoff DF. Cancer. Developing molecular biomarkers for cancer. Science 2003;299:1679-80.
513	31.	Bell AC, Felsenfeld G. Methylation of a CTCF-dependent boundary controls imprinted expression of the Igf2 gene.
514		Nature 2000;405:482-5.
515	32.	Cruz-Correa M, Cui H, Giardiello FM, et al. Loss of imprinting of insulin growth factor II gene: a potential
516		heritable biomarker for colon neoplasia predisposition. Gastroenterology 2004;126:964-70.
517	33.	Cui H. Loss of imprinting of IGF2 as an epigenetic marker for the risk of human cancer. Dis Markers
518		2007;23:105-12.
519	34.	Ito Y, Koessler T, Ibrahim AE, et al. Somatically acquired hypomethylation of IGF2 in breast and colorectal cancer.
520		Hum Mol Genet 2008;17:2633-43.
521	35.	Cancer Genome Atlas N. Comprehensive molecular characterization of human colon and rectal cancer. Nature
522		2012;487:330-7.
523	36.	Bosman. FT. Cancer by organ site: Colorectal cancer. In: Bernard W. Stewart CPW, ed. World Cancer Report 2014.
524		International Agency for Research on Cancer, WHO 2014:560-576.
525	37.	Ohta M, Sugimoto T, Seto M, et al. Genetic alterations in colorectal cancers with demethylation of insulin-like
526		growth factor II. Hum Pathol 2008;39:1301-8.
527	38.	Lonning PE, Berge EO, Bjornslett M, et al. White Blood Cell BRCA1 Promoter Methylation Status and Ovarian
528		Cancer Risk. Ann Intern Med 2018;168:326-34.
529	39.	Heiss JA, Brenner H. Impact of confounding by leukocyte composition on associations of leukocyte DNA
530		methylation with common risk factors. Epigenomics 2017;9:659-68.
531		

532 Figures

- **Figure 1.** Flow chart of participants included and analysed in the (A) initial and (B) validation
- studies. COAD, colon adenocarcinoma; CRC, colorectal cancer; EPIC-Italy, the European
- 535 Prospective Investigation into Cancer and nutrition (EPIC cohort) in Italy; GEO, Gene Expression
- 536 Omnibus; READ, rectum adenocarcinoma; TCGA, The Cancer Genome Atlas.
- 537



Figure 2. MS-HRM assay to detect methylation levels at the IGF2 promoter region. Our assay encompassed 539 a 101 bp region (range: chr11: 2139870-2139971, including 11 CpGs), which located in the promoter of 540 541 human IGF2 gene and near the transcription start site (TSS). Arrows indicate position and direction of MS-HRM primers. **Black dashes** () indicate individual CpGs on DMR region tested in our study. **Black** 542 **Dots** (\bullet) indicate six methylation probes (including cg17434309, cg05859777, cg01667319, cg05452899, 543 cg10037494, cg26517849) on the Illumina Infinium HumanMethylation450 BeadChip, which overlap CpG 544 sites detected in our DMR region. *The TSS±1500 region is an expanded region of -1500 bp upstream to 545 +1500 downstream from the TSS (range: chr11: 2137890-2140889). To test the robustness of our results, we 546 further assess the association of methylation levels of this expanded region with CRC risk. In the TSS±1500 547 region, a total of 32 CpG sites were detected by the Infinium HumanMethylation450 methylation probes. 548 The methylation probes are as follows: cg25163476, cg24917382, cg24366657, cg23905216, cg23676551, 549 cg22287492, cg21667878, cg20339650, cg19443075, cg19371526, cg19002337, cg18087943, cg17434309, 550 cg17037101, cg16415340, cg15393937, cg14608156, cg14188639, cg13756879, cg12773325, cg12614029, 551 cg11915650, cg10659464, cg10037494, cg09694722, cg08162473, cg05859777, cg05452899, cg04072545, 552 cg03760951, cg02835822, cg01667319. 553

554

IGF2



- **Figure 3.** The results for the association between PBL IGF2 methylation and the risk of developing CRC (A) in the initial and validation
- 557 studies, and (**B**) in the combined populations.
- *A total of 14 covariates were included in the propensity score model in the initial case-control study (see supplementary table S3). In the
- validation studies, gender and age were included in the propensity score model for GSE51032 and age for GSE89093, respectively.
- To be conservative, we pooled the results from these three datasets with a random effect model in the meta-analysis. BMI, body mass
- index; CI, confidence interval; Hyper-, IGF2 hypermethylation; Hypo-, IGF2 hypomethylation; OR, odds ratio.
 - Α

No. case / No. co		/ No. control				
Groups	Нуро-	Hyper-	OR _{PS-adjusted} (95% CI) 1	r-value		
Initial study						
Colorectal cancer	334/389	94/39	2.57 (1.65, 4.03)	<0.0001		
Subgroups						
Tumor site						
Colon cancer	134/389	44/39	2.85 (1.69, 4.82)	0.0001		
Rectum cancer	200/389	50/39	2.53 (1.58, 4.06)	0.0001		
UICC stage						
I + II	184/389	47/39	2.21 (1.32, 3.70)	0.0026		
III	118/389	42/39	3.34 (1.99, 5.73)	<0.0001		
IV	14/389	1/39 🗲 🔳 –	0.65 (0.09, 5.16)	0.6881		
Gender						
Male https://doi.org	207/245	59/21	2.87 (1.58, 5.22)	0.0005		
n was noeneelie in was noeneelie in was not be the second se	er rev i@v) /ib4t4e	aut B5r/fu nder, who ha	s granted medRx a license to display the preprint in perpetuity 2.23 (1.14, 4.37)	0.0190		
Age (vrs)	It is made av	vailable under a CC-B	4 4.0 International license .			
< 60	181/198	38/19	1.92 (1.01, 3.66)	0.0461		
≥ 60	153/191	56/20	3.39 (1.81, 6.34)	0.0001		
BMI (Kg/m ²)						
< 24	184/153	63/19	2.72 (1.53, 4.86)	0.0007		
≥ 24	150/236	31/20	2.41 (1.18, 4.91)	0.0153		
GSE51032						
Colorectal cancer	136/391	30/33	2.21 (1.28, 3.81)	0.0042		
Subaroups						
Tumor site						
Colon cancer	124/382	30/33	2.41 (1.40, 4.17)	0.0016		
Rectum cancer	12/382	0/33		-		
Gender						
Male	67/80	20/4	5.98 (1.94, 18.36)	0.0018		
Female	69/311	10/29	1.35 (0.61, 2.95)	0.4603		
Age (yrs)						
< 60	109/323	19/25	1.82 (0.95, 3.49)	0.0708		
≥ 60	27/68	11/8	3.42 (1.21, 9.71)	0.0208		
GSE89093						
Colorectal cancer	1/23	11/23	10.65 (1.26, 89.71)	0.0295		
Subarouns						
Tumor site			· •			
Colon cancer	1/23	9/23	8.65 (1.00, 74.28)	0.0493		
Rectum cancer	0/23	2/23		-		
	5/20					
		.5	1 2 5 10 20			

Study

OR (95% CI) P-value Weight (%)



562

563 Figure 4. IGF2 methylation in PBLs and CRC prognosis in the initial cohort. Kaplan-Meier plots for

(A) overall survival, (B) CRC specific survival, and (C) disease-free survival according to IGF2

565 methylation status in PBLs in CRC patients. (D) Associations of *IGF2* methylation in PBLs with

566 CRC prognosis during different follow-up periods. CI, confidence interval; CRC, colorectal cancer;

567 CSS, cancer specific survival; DFS, disease free survival; HR, hazard ratio; Hyper-, IGF2

⁵⁶⁸ hypermethylation; Hypo- IGF2 hypomethylation; OS, overall survival; PBL, peripheral blood

569 leukocyte.



- 572 Figure 5. Kaplan-Meier curves for IGF2 methylation in PBLs and CRC overall survival in the
- 573 EPIC-Italy cohort. CI, confidence interval; HR, hazard ratio; Hyper-, IGF2 hypermethylation; Hypo-
- 574 IGF2 hypomethylation.



- 576 **Figure 6.** The association between IGF2 methylation in tumour tissues and CRC patient prognosis.
- 577 Kaplan-Meier curves for overall survival according to IGF2 methylation status in tumour tissues of
- 578 CRC patients in (A) the initial cohort and (B) TCGA datasets. (C) The correlation between IGF2
- 579 mRNA expression level and methylation level of the differentially methylated region of IGF2 tested
- in our study using the TCGA dataset. (D) Kaplan-Meier curves for overall survival according to
- 581 IGF2 mRNA expression levels in tumour tissues of CRC patients in the TCGA cohort.
- 582 CI, confidence interval; CRC, colorectal cancer; HR, hazard ratio.



- **Figure 7.** Sensitivity analyses using the confounding RR method. The confounding RR was defined
- as the ratio of the PS-adjusted effect estimates and the unadjusted effect estimates.
- 586 CI, confidence interval; CRC, colorectal cancer; CSS, cancer specific survival; DFS, disease free
- survival; HR, hazard ratio; OR, odds ratio; OS, overall survival; PS, propensity score.



Figure 8. The associations between IGF2 methylation in tissue samples and CRC risk in the datasets from GEO and TCGA. (A) Adenoma or tumour

tissues versus normal colorectal mucosa in the GEO datasets. (B) Tumour tissues versus normal colorectal mucosa in the TCGA datasets. (C) Tumour

tissues versus matched adjacent normal tissues in the datasets from (C) GEO and (D) TCGA. (E) The discrimination performance of IGF2 methylation

in tissue samples to identify CRC tumour or adenoma tissue and normal colorectal mucosa in the datasets from GEO and TCGA. (F) The IGF2 methylation levels in normal colorectal mucosa, adenoma and tumour tissue samples in the GEO datasets. *indicates P<0.0001, and ns indicates not

methylation levels in normal colorectal mucosa, adenoma and tumour tissue samples in the GEO datasets. *indicates P<0.0001, and ns indicates n statistical significance. AUC, the area under receiver operating characteristic curves; CI, confidence interval; OR, odds ratio; Hyper-, IGF2

596 hypermethylation; Hypo-, IGF2 hypomethylation;



599 Figure 9. The interaction between PBL IGF2 methylation and serum CEA levels on CRC patient

prognosis using the additive and multiplicative models. (A) The interaction analysed with the

additive model. (B) The effect estimates for interaction in respected to both the additive and

multiplicative models. AP, attributable proportion due to interaction; CI, confidence interval; HR,

- hazard ratio; Hyper-, IGF2 hypermethylation; Hypo-, IGF2 hypomethylation; PBL, peripheral blood
- leukocyte; RERI, relative excess risk due to interaction; SI, synergy index; V index, the
- 605 multiplicative interaction index.





в

	IGF2 Methyla	Effect for Interaction (95% CI)					
CEA Level (na/mL)	Hypomethylation	Ad	ditive interact	Multiplicative interaction			
(HR _{eg} (S	RERI	AP	SI	V index		
Higher (> 5)	1	0.44 (0.24-0.79)	0.54	1.49	0.54	2.10	
Lower (≤ 5)	0.38 (0.24-0.61)	0.36 (0.20-0.65)	(0.18-0.90)	(0.46-2.52)	(0.37-0.80)	(0.86-5.15)	

Subgroups		Univariate HR, 95% CI	P-value	PS-adjusted HR, 95% CI	P-value	P-value for heterogeneity*
Tumour Site						
05	Colon	0.65 (0.33-1.27)	0.2049	0.59 (0.29-1.17)	0.1309	0.4117
03	Rectum	0.49 (0.28-0.86)	0.0132	0.39 (0.20-0.77)	0.0065	0.4117
CSS	Colon	0.60 (0.29-1.21)	0.1545	0.55 (0.27-1.13)	0.1062	0.6706
035	Rectum	0.53 (0.30-0.94)	0.0293	0.45 (0.22-0.88)	0.0204	0.0700
Subgroups Tumour Site OS CSS DFS OS DFS OS DFS OS <	Colon	0.51 (0.25-1.05)	0.0661	0.48 (0.23-1.00)	0.0514	0.7520
	Rectum	0.68 (0.39-1.18)	0.1714	0.56 (0.29-1.09)	0.0895	0.7339
UICC Stage						
	I + II + III	0.58 (0.37-0.90)	0.0158	0.45 (0.28-0.74)	0.0017	
05	I + II	0.57 (0.27-1.21)	0.1427	0.35 (0.15-0.82)	0.0155	
Subgroups Tumour Site OS CSS DFS OS CSS DFS Gender OS CSS DFS Age, (years) OS CSS DFS BMI, (Kg/m2 OS CSS DFS	III	0.54 (0.31-0.95)	0.0327	0.54 (0.30-0.98)	0.0440	0.5840
	IV	1.04 (0.13-8.38)	0.9726	0.94 (0.11-8.08)	0.9542	
	I + II + III	0.59 (0.37-0.93)	0.0243	0.47 (0.29-0.78)	0.0037	
CSS	I + II	0.59 (0.27-1.30)	0.1880	0.39 (0.16-0.97)	0.0427	
Subgroups Tumour Site OS ICSS DFS OS JCSS Gender OS Gender OS Age, (years) OS DFS SOS OS DFS DFS OS	III	0.55 (0.31-0.97)	0.0375	0.54 (0.30-0.98)	0.0441	0.7135
	IV	1.04 (0.13-8.38)	0.9726	0.94 (0.11-8.08)	0.9542	
	I + II + III	0.64 (0.40-1.00)	0.0508	0.51 (0.31-0.84)	0.0084	
DEC	I + II	0.63 (0.29-1.37)	0.2435	0.41 (0.17-0.99)	0.0471	
DFS	III	0.61 (0.35-1.06)	0.0812	0.60 (0.33-1.10)	0.0974	0.7337
	IV	0.67 (0.08-5.34)	0.7048	0.75 (0.09-6.55)	0.7982	
Gender						
20	Female	0.72 (0.39-1.32)	0.2910	0.50 (0.24-1.04)	0.0626	0 (172
Tumour Site OS OS DFS UICC Stage OS CSS OFS Gender OS CSS OFS Age, (years) OS CSS DFS BMI, (Kg/m2 OS	Male	0.40 (0.21-0.76)	0.0054	0.39 (0.20-0.77)	0.0066	0.0172
CCC	Female	0.74 (0.39-1.40)	0.3552	0.55 (0.26-1.16)	0.1163	0.5527
Tumour Site OS CSS DFS UICC Stage OS CSS DFS Gender OS CSS DFS Age, (years) OS CSS DFS SOS OS CSS DFS OS OS OS OS OS OS OS OS OS CSS DFS OS OS OS DFS	Male	0.41 (0.22-0.79)	0.0071	0.40 (0.20-0.79)	0.0086	0.3327
Tumour Site OS CSS DFS OS OS <td>Female</td> <td>0.75 (0.40-1.42)</td> <td>0.3789</td> <td>0.55 (0.26-1.16)</td> <td>0.1184</td> <td>0.7601</td>	Female	0.75 (0.40-1.42)	0.3789	0.55 (0.26-1.16)	0.1184	0.7601
	Male	0.49 (0.26-0.90)	0.0226	0.48 (0.25-0.92)	0.0277	0.7691
Age, (years)						
05	< 60	0.54 (0.27-1.06)	0.0719	0.53 (0.26-1.11)	0.0948	0 6705
03	≥ 60	0.54 (0.30-0.95)	0.0339	0.43 (0.23-0.81)	0.0082	0.0703
CSS	< 60	0.55 (0.28-1.08)	0.0804	0.56 (0.27-1.17)	0.1211	0 (522
Tumour SiteColor RectureOSColor RectureCSSColor RectureDFSColor RectureDFSIOSIIIOSII <td>≥ 60</td> <td>0.56 (0.31-1.01)</td> <td>0.0555</td> <td>0.45 (0.23-0.85)</td> <td>0.0144</td> <td>0.0333</td>	≥ 60	0.56 (0.31-1.01)	0.0555	0.45 (0.23-0.85)	0.0144	0.0333
DEC	< 60	0.60 (0.30-1.18)	0.1379	0.68 (0.30-1.30)	0.2123	0.5624
DFS	≥ 60	0.59 (0.33-1.05)	0.0747	0.47 (0.25-0.89)	0.0197	0.5624
BMI, (Kg/m2	2)					
05	< 24	0.52 (0.30-0.88)	0.0144	0.47 (0.27-0.85)	0.0119	0.0047
05	≥ 24	0.56 (0.25-1.23)	0.1473	0.48 (0.21-1.07)	0.0726	0.9947
CSS	< 24	0.56 (0.33-0.97)	0.0370	0.53 (0.29-0.95)	0.0333	0.7016
C22	≥24	0.49 (0.21-1.14)	0.0984	0.43 (0.18-1.02)	0.0557	0.7016
DEC	< 24	0.61 (0.36-1.04)	0.0689	0.54 (0.30-0.97)	0.0378	0.9740
DFS	> 2.4	0 51 (0 22-1 20)	0 1234	0 49 (0 21-1 18)	0 1127	0.8742

Table 1. Subgroup analysis for the association of PBL IGF2 methylation with CRC prognosis.

*Test for heterogeneity between ORs was conducted by using random effect models with Comprehensive Meta

Analysis (version 2.2.046). BMI, body mass index; CI, confidence interval; CRC, colorectal cancer; CSS, cancer

610 specific survival; DFS, disease free survival; HR, hazard ratio; OS, overall survival; PBL, peripheral blood leukocyte;

611 PS, propensity score.

612 Supplementary Files

- Supplementary File 1A. Main characteristics of participants of the initial and validation studies in the
- 614 CRC risk analysis.
- 615 Supplementary File 1B. Main characteristics of patients of the initial and validation cohorts in the CRC
- 616 prognosis analysis.
- 617 Supplementary File 2A. Comparisons of participant characteristics and covariates between CRC cases
- and controls before and after propensity score adjustment in the initial case-control study in CRC risk
- 619 analysis.
- 620 Supplementary File 2B. Comparisons of baseline characteristics of CRC patients before and after
- 621 propensity score adjustment in the initial cohort in CRC prognosis analysis.
- 622 Supplementary File 3A. Sensitivity analyses using additional propensity score based methods for CRC
- risk analysis in the initial case-control study.
- 624 Supplementary File 3B. Sensitivity analyses using additional propensity score based methods for CRC
- survival analysis in the initial CRC cohort.
- 626 Supplementary File 4. E-values for PS-adjusted effect estimates.
- 627 Supplementary File 5. Associations between PBL IGF2 methylation status and UICC stage, serum CEA
- level, WBC counts, and whether or not included in the survival analysis among CRC patients.
- 629 Supplementary File 6. Associations of PBL IGF2 methylation and CRC patient prognosis with or
- 630 without WBC counts included in PS models.



CRC Prognosis Analysis

Blood Samples

The EPIC-Italy Cohort (n=166)

Tissue Samples

TCGA



IGF2



Groupo	No. case	/ No. control						OB (95% CI)	D voluo
Groups	Нуро-	Hyper-						OR _{PS-adjusted} (95% CI)	P-value
Initial study									
Colorectal cancer	334/389	94/39						2.57 (1.65, 4.03)	<0.0001
Subgroups			:						
Tumor site			:						
Colon cancer	134/389	44/39	÷ —		_			2.85 (1.69, 4.82)	0.0001
Rectum cancer	200/389	50/39	÷ —					2.53 (1.58, 4.06)	0.0001
UICC stage									
+	184/389	47/39						2.21 (1.32, 3.70)	0.0026
111	118/389	42/39	÷ –					3.34 (1.99, 5.73)	<0.0001
IV	14/389	1/39 🗲 🗖	<u>.</u>					0.65 (0.09, 5.16)	0.6881
Gender			:						
Male	207/245	59/21	÷					2.87 (1.58, 5.22)	0.0005
Female	127/144	35/18			-			2.23 (1.14, 4.37)	0.0190
Age (vrs)									
< 60	181/198	38/19						1.92 (1.01, 3.66)	0.0461
≥ 60	153/191	56/20	÷ —					3.39 (1.81, 6.34)	0.0001
BMI (Kg/m ²)									
< 24	184/153	63/19			_			2.72 (1.53, 4.86)	0.0007
22 dRxiv preprint doi: http://which.was.not.certifie	s://dei org/10-110 ed by peer review	1/2822/0427.22274374;) is the a uthor/funder, w	this vers <u>ion posted April</u> ho has granted medRxiv	28-2022. The copy a license to display	<u>rriah</u> t holder for this the preprint in perp	s preprint petuity.		2.41 (1.18, 4.91)	0.0153
GSE51032	It is	made available under a	CC-BY 4.0 International	license .					
Colorectal cancer	136/391	30/33	: <u> </u>					2.21 (1.28, 3.81)	0.0042
Subgroups			:						
Tumor site									
Colon cancer	124/382	30/33		-				2.41 (1.40, 4.17)	0.0016
Rectum cancer	12/382	0/33						-	-
Gender			÷						
Male	67/80	20/4			-			5.98 (1.94, 18.36)	0.0018
Female	69/311	10/29 —						1.35 (0.61, 2.95)	0.4603
Age (yrs)									
< 60	109/323	19/25	÷					1.82 (0.95, 3.49)	0.0708
≥ 60	27/68	11/8						3.42 (1.21, 9.71)	0.0208
GSE89093									
Colorectal cancer	1/23	11/23	· · · · · · · · · · · · · · · · · · ·				>	10.65 (1.26, 89.71)	0.0295
Subgroups			÷						
Tumor site									
Colon cancer	1/23	9/23					>	8.65 (1.00, 74.28)	0.0493
Rectum cancer	0/23	2/23	:					-	-
		<u> </u>							
		.5	1 2		5	10	20		

Α









Survival Time (days)









В







В

	IGF2 Methyla	Effect for Interaction (95% CI)					
(na/mL)	Hypomethylation	Ade	ditive interact	Multiplicative interaction			
(3)	HR _{eg} (S	RERI	AP	SI	V index		
Higher (> 5)	1	0.44 (0.24-0.79)	0.54	1.49	0.54	2.10	
Lower (≤ 5)	0.38 (0.24-0.61)	0.36 (0.20-0.65)	(0.18-0.90)	(0.46-2.52)	(0.37-0.80)	(0.86-5.15)	